First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Subscribe To Our Newsletter & Stay Updated
